Abstract
Since the discovery of stem cells, scientists have invested tremendous effort in establishing in vitro culture conditions in order to maintain the self-renewal and efficient proliferative capabilities of stem cells by manipulating a variety of growth factors. Fibroblast growth factor (FGF) is one of the most common growth factors used to expand stem cells, including human embryonic stem (hES) cells and several tissue type-specific stem cells. Moreover, it has been recently recognized that FGF is useful for culturing cancer stem cells derived from various types of human tumor tissues, such as brain and breast tumors. The molecular mechanisms underlying the control of stemness by FGF have remained elusive for a long time. The main signal transduction pathway initiated at the FGF receptors leads to the activation of Ras/ERK pathways via the control center FRS2α. Recent emerging evidence suggests that the FGF-ERK axis controls stemness via multiple modes of action. I would like to summarize current understanding of this subject from recent discoveries in this field.
Keywords: FRS2, adaptor, embryonic stem (ES) cells, iPS cells, trophoblast stem (TS) cells, neural stem cells
Current Stem Cell Research & Therapy
Title: Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells
Volume: 4 Issue: 1
Author(s): Noriko Gotoh
Affiliation:
Keywords: FRS2, adaptor, embryonic stem (ES) cells, iPS cells, trophoblast stem (TS) cells, neural stem cells
Abstract: Since the discovery of stem cells, scientists have invested tremendous effort in establishing in vitro culture conditions in order to maintain the self-renewal and efficient proliferative capabilities of stem cells by manipulating a variety of growth factors. Fibroblast growth factor (FGF) is one of the most common growth factors used to expand stem cells, including human embryonic stem (hES) cells and several tissue type-specific stem cells. Moreover, it has been recently recognized that FGF is useful for culturing cancer stem cells derived from various types of human tumor tissues, such as brain and breast tumors. The molecular mechanisms underlying the control of stemness by FGF have remained elusive for a long time. The main signal transduction pathway initiated at the FGF receptors leads to the activation of Ras/ERK pathways via the control center FRS2α. Recent emerging evidence suggests that the FGF-ERK axis controls stemness via multiple modes of action. I would like to summarize current understanding of this subject from recent discoveries in this field.
Export Options
About this article
Cite this article as:
Gotoh Noriko, Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells, Current Stem Cell Research & Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488809787169048
DOI https://dx.doi.org/10.2174/157488809787169048 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of mTOR in Hematological Malignancies
Current Cancer Therapy Reviews Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone
Recent Patents on Anti-Cancer Drug Discovery Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy
Current Pharmaceutical Design CD123: A Novel Biomarker for Diagnosis and Treatment of Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery
Current Drug Targets Novel Patents and Cancer Therapies for Transforming Growth Factor- Beta and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Progress of Computer-Aided Drug Design (CADD) of Proteasome Inhibitors
Current Topics in Medicinal Chemistry International Publication Trends in Proteasome Inhibitors: From Tools for Cell Biologists to Anticancer Agents
Letters in Drug Design & Discovery Morphine Stimulates Vascular Endothelial Growth Factor-Like Signaling in Mouse Retinal Endothelial Cells
Current Neurovascular Research Monoclonal Antobodies: Application in Radiopharmacy
Current Radiopharmaceuticals Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Current Enzyme Inhibition Disorders of Protein Biogenesis and Stability
Protein & Peptide Letters COVID-19-associated Coagulopathy and Thromboembolism: Determination of Their Patterns and Risk Factors as Predictors of Mortality Among Severe COVID-19 Patients
Current Vascular Pharmacology Current Targets for Anticancer Drug Discovery
Current Drug Targets Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry